Vir Biotechnology Inc (VIR)

10:28 AM

Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus - MSN

10:28 AM

10:15 AM

Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint - Yahoo Finance

10:15 AM

May 09, 2025

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study - BioSpace

May 09, 2025

May 09, 2025

Vir Biotechnology (VIR) Reveals Promising Data in Hepatitis B Treatment - GuruFocus

May 09, 2025

May 09, 2025

Vir Biotechnology Presents Promising Phase 2 Hepatitis B Data - TipRanks

May 09, 2025

May 09, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 09, 2025

May 09, 2025

Vir posts mid-stage trial data for Hep B drug (VIR:NASDAQ) - Seeking Alpha

May 09, 2025

May 09, 2025

Vir Biotechnology’s Earnings Call: Mixed Sentiment Amid Progress - TipRanks

May 09, 2025

May 09, 2025

Vir Biotechnology (VIR) Unveils Promising Hepatitis B Treatment Data | VIR Stock News - GuruFocus

May 09, 2025

May 09, 2025

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | VIR Stock News - GuruFocus

May 09, 2025

May 08, 2025

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment - Seeking Alpha

May 08, 2025

May 08, 2025

Vir Biotechnology Reports Q1 2025 Financial Results - TipRanks

May 08, 2025

May 08, 2025

Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance

May 08, 2025

May 08, 2025

Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Advancements - GuruFocus

May 08, 2025

May 08, 2025

Vir Biotechnology Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 08, 2025

May 08, 2025

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results - BioSpace

May 08, 2025

May 07, 2025

Vir Biotechnology Q1 2025 Earnings Call Transcript - MarketBeat

May 07, 2025

May 07, 2025

Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq

May 07, 2025

May 07, 2025

Earnings call transcript: Vir Biotech Q1 2025 reports increased R&D expenses - Investing.com

May 07, 2025

May 07, 2025

Vir Biotechnology (VIR) Falls Short on Q1 Revenue, Advances Clinical Programs | VIR Stock News - GuruFocus

May 07, 2025

May 07, 2025

Vir Biotechnology Inc. (VIR) Misses Q1 EPS by 1c - StreetInsider

May 07, 2025

May 07, 2025

Vir Biotechnology Q1 2025 Earnings Preview - MSN

May 07, 2025

May 06, 2025

Earnings Outlook For Vir Biotechnology - Nasdaq

May 06, 2025

May 05, 2025

Vir Biotechnology Inc expected to post a loss of 84 cents a shareEarnings Preview - TradingView

May 05, 2025

May 05, 2025

(VIR) On The My Stocks Page - news.stocktradersdaily.com

May 05, 2025

May 03, 2025

BlackRock, Inc. Reduces Stake in Vir Biotechnology Inc. - GuruFocus

May 03, 2025

May 01, 2025

Will Vir Biotech's Hepatitis B And D Data Presentations Give The Stock A Much-Needed Boost? - RTTNews

May 01, 2025

Apr 30, 2025

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025 - BioSpace

Apr 30, 2025

Apr 25, 2025

Vir Biotechnology SVP sells shares for $14,291 - MSN

Apr 25, 2025

Apr 25, 2025

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver Congress 2025 - marketscreener.com

Apr 25, 2025

Apr 24, 2025

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 - BioSpace

Apr 24, 2025

Apr 24, 2025

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 | VIR Stock News - GuruFocus

Apr 24, 2025

Apr 19, 2025

When (VIR) Moves Investors should Listen - news.stocktradersdaily.com

Apr 19, 2025

Apr 17, 2025

5 Analysts Have This To Say About Vir Biotechnology - Benzinga

Apr 17, 2025

Apr 16, 2025

Lobbying Update: $50,000 of VIR BIOTECHNOLOGY INC. lobbying was just disclosed - Nasdaq

Apr 16, 2025

Apr 10, 2025

New Mpro inhibitors revealed in Vir Biotechnology patent - BioWorld MedTech

Apr 10, 2025

Apr 09, 2025

Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple - Insider Monkey

Apr 09, 2025

Apr 08, 2025

10 Stocks Under $10 that Will Triple - Insider Monkey

Apr 08, 2025

Apr 05, 2025

Vir Biotechnology CEO Marianne de Backer sells $474,238 in stock By Investing.com - Investing.com South Africa

Apr 05, 2025

Apr 04, 2025

Vir Biotechnology CEO Marianne de Backer sells $474,238 in stock - Investing.com

Apr 04, 2025

Apr 04, 2025

Vir Biotechnology CEO Sells Shares to Cover Tax Obligations - TradingView

Apr 04, 2025

Apr 03, 2025

Vir Biotechnology stock hits 52-week low at $6.07 By Investing.com - Investing.com Australia

Apr 03, 2025

Apr 03, 2025

Vir Biotechnology stock hits 52-week low at $6.07 - Investing.com

Apr 03, 2025

Apr 01, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Apr 01, 2025

Mar 31, 2025

Vir Biotechnology Insiders Sell US$1.3m Of Stock, Possibly Signalling Caution - simplywall.st

Mar 31, 2025

Mar 28, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company - Yahoo

Mar 28, 2025

Mar 26, 2025

Vir Biotechnology stock hits 52-week low at $6.54 By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

Vir Biotechnology stock hits 52-week low at $6.54 - Investing.com India

Mar 26, 2025

Mar 24, 2025

(VIR) Trading Advice - news.stocktradersdaily.com

Mar 24, 2025

Mar 21, 2025

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results - Quantisnow

Mar 21, 2025